ZYKADIA
PeakNDAORALCAPSULEPriority Review
Approved
Apr 2014
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
ZYKADIA by Novartis is inhibitor. First approved in 2014.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYKADIA is an oral small-molecule capsule approved by Novartis in April 2014 for a currently unspecified indication. The exact mechanism of action and therapeutic target are not documented in the provided data, limiting characterization of its clinical role.
Peak5.6 years to LOE
Product is in peak commercial phase with sustained market presence, suggesting stable team size and mature commercial operations at Novartis.
Mechanism of Action
inhibitor. Targets of ceritinib inhibition identified in either biochemical or cellular assays at clinically relevant concentrations include ALK, insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1. Among these, ceritinib is most active against ALK. Ceritinib inhibited…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZYKADIA currently has zero linked job openings, reflecting either a mature commercial team or limited expansion plans. Career opportunities would primarily be in brand management, market access, and field roles focused on maintaining market share through 2032.
Worked on ZYKADIA at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.